Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 10 vs DAYPRO ALTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Rheumatoid arthritis,Osteoarthritis,Juvenile idiopathic arthritis,Ankylosing spondylitis (off-label),Acute gout (off-label)
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
50-65 hours (mean 57 hours); clinically significant accumulation occurs with multiple dosing, requiring dose adjustment in elderly and renal impairment.
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Primarily hepatic via cytochrome P450 (CYP) 2C9 and CYP2C8; minor metabolism via glucuronidation. Metabolites are inactive.
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
Renal: 85% (60-90% as oxaprozin glucuronide and 5-10% as unchanged oxaprozin); Fecal: <5%; Biliary: negligible.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
>99.5% bound to albumin.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
0.15-0.25 L/kg; low Vd indicates extensive plasma protein binding and limited tissue distribution.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
Oral: approximately 100% (well absorbed with no significant first-pass metabolism).
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
For patients with creatinine clearance (Cr Cl) of 50-79 m L/min: no dose adjustment is generally required, but monitor for adverse effects. For Cr Cl 30-49 m L/min: reduce dose by 50% or use 600 mg once daily. For Cr Cl <30 m L/min: use is contraindicated. End-stage renal disease (ESRD): avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Child-Pugh Class A (mild impairment): no dose adjustment needed. Child-Pugh Class B (moderate impairment): reduce dose by 50% or use 600 mg once daily; monitor closely. Child-Pugh Class C (severe impairment): use is contraindicated. No specific studies; caution advised.
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
Not approved for pediatric use. Safety and efficacy have not been established in patients under 18 years. Avoid use in children and adolescents unless under expert guidance and with caution.
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
Elderly patients (≥65 years) are at increased risk for NSAID-related adverse effects, including GI bleeding, renal impairment, and cardiovascular events. Initiate therapy at the lowest effective dose (e.g., 600 mg once daily) and monitor renal function, blood pressure, and for signs of GI toxicity. Avoid use if possible in patients with high cardiovascular risk or history of GI ulceration.
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Cardiovascular risk: NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Gastrointestinal risk: NSAIDs increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines, which can be fatal. These events can occur at any time without warning.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
Cardiovascular thrombotic events (MI, stroke),Gastrointestinal bleeding, ulceration, perforation,Renal toxicity (elevated creatinine, nephrotoxicity),Hepatic effects (transaminase elevations, rare severe hepatotoxicity),Hypertension exacerbation,Fluid retention and edema,Anaphylactoid reactions,Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome),Premature closure of ductus arteriosus in pregnancy,Hematologic effects (anemia, bleeding)
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
Hypersensitivity to oxaprozin or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In setting of coronary artery bypass graft (CABG) surgery,Advanced renal disease,Pregnancy (third trimester) due to risk of preterm closure of ductus arteriosus and oligohydramnios
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
May be taken with food or milk to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of GI bleeding. No specific food restrictions otherwise.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimester: Avoid after 30 weeks due to premature closure of ductus arteriosus and oligohydramnios. DAYPRO ALTA (oxaprozin) is contraindicated in third trimester.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
Oxaprozin is excreted in human milk; M/P ratio is approximately 0.5. Due to potential adverse effects on infant, caution is advised. Use only if benefit outweighs risk, consider alternative agents.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
In pregnancy, oxaprozin clearance may increase; however, no specific dose adjustment is recommended. Use lowest effective dose for shortest duration during first and second trimesters. Avoid in third trimester.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Daypro Alta (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~40-50 hours) allowing once-daily dosing. Monitor for GI bleeding, renal impairment, and cardiovascular events. Use with caution in elderly and those with renal insufficiency. Avoid in patients with aspirin-sensitive asthma or NSAID allergy.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
Take with food or milk to reduce stomach upset.,Do not take other NSAIDs or aspirin while on this medication.,Report any signs of stomach bleeding (black stools, coffee-ground vomit), chest pain, or swelling.,Avoid alcohol as it increases GI bleeding risk.,Tell your doctor about all medications, especially blood thinners and diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 10 vs DAYPRO ALTA, answered by our medical review team.
ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. DAYPRO ALTA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 10 and DAYPRO ALTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. The standard adult dose of DAYPRO ALTA is: Oxaprozin is administered orally. The usual adult dose is 1200 mg once daily. For osteoarthritis and rheumatoid arthritis, dosing can range from 600 to 1200 mg once daily. A starting dose of 600 mg once daily may be considered for patients with low body weight or milder disease.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 10 and DAYPRO ALTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. DAYPRO ALTA is classified as Category C. First trimester: NSAIDs are not associated with a major teratogenic risk, but avoid due to potential risk of miscarriage. Second trimester: Use only if clearly needed. Third trimes. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.